Companies › Imara
1 active drug program in 1 registered trial: 1 Phase 2; Hematology.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Tovinontrine (IMR-687) Phosphodiesterase 9A inhibitor | PDE9A | Phase 2 | Sickle Cell Disease | – |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT04053803 | Tovinontrine (IMR-687) | Phase 2 | Sickle Cell Disease | Hematology | Mar 2025 |
–
S-INFINITY Pharmaceuticals Prothya Biosolutions Shanghai RAAS Blood Products Pharmanutra Vega Therapeutics
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.